RESUMO
Cells with 'signet-ring' appearance were found at post-mortem examination of a man with a history of chronic illness, weight loss and multiple regions of 'bowel thickening' during life. Due to the decedent's history, the finding raised the possibility of disseminated signet-ring adenocarcinoma. However, the vacuoles did not stain for mucin and the cells did not stain for keratin. The cells did stain for calretinin and so a diagnosis of signet ring mesothelioma was considered. However, it was suggested that the cells with a cytoplasmic vacuole displacing the nucleus to one side producing the signet-ring appearance were instead atrophic fat cells. This was subsequently proven by Oil Red O staining.
Assuntos
Adipócitos/patologia , Atrofia/patologia , Carcinoma de Células em Anel de Sinete , Citoplasma/patologia , Diagnóstico Diferencial , Humanos , Masculino , Mesotelioma , Pessoa de Meia-Idade , Coloração e Rotulagem , Vacúolos/patologiaRESUMO
Herein we report a case of sporadic inclusion-body myositis (sIBM) occurring at an unusually young age in a patient with primary Sjögren syndrome, and use the case to explore possible shared mechanisms for disease susceptibility. Possible factors may include the association of both conditions with the 8.1 ancestral haplotype; the presence of anti-cN1A antibodies, which, although considered specific for sIBM, are also seen in pSS; and the shared association with T-cell large granular lymphocyte leukemia (T-LGLL). Further evaluation of this patient did in fact reveal underlying T-LGLL and mechanisms by which T cells in sIBM may escape immune regulation and contribute to disease phenotype are explored. Despite myofiber infiltration with CD8-positive T cells in sIBM, and, although sIBM is traditionally considered treatment-refractory, we report a significant response to the anti-CD20 monoclonal antibody, rituximab, and discuss possible mechanisms by which this response may be mediated.
Assuntos
5'-Nucleotidase/imunologia , Autoanticorpos/imunologia , Leucemia Linfocítica Granular Grande/imunologia , Miosite de Corpos de Inclusão/imunologia , Síndrome de Sjogren/imunologia , Adulto , Azatioprina/uso terapêutico , Linfócitos T CD8-Positivos/patologia , Feminino , Antígenos HLA/genética , Haplótipos , Humanos , Hidroxicloroquina/uso terapêutico , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Leucemia Linfocítica Granular Grande/complicações , Imageamento por Ressonância Magnética , Metotrexato/uso terapêutico , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/patologia , Miosite de Corpos de Inclusão/complicações , Miosite de Corpos de Inclusão/patologia , Miosite de Corpos de Inclusão/terapia , Prednisolona/uso terapêutico , Rituximab/uso terapêutico , Síndrome de Sjogren/complicações , Síndrome de Sjogren/terapiaRESUMO
Background: Myoadenylate deaminase (MAD) deficiency is a form of metabolic myopathy, which generally causes only mild symptoms in the primary inherited form. Inflammatory myopathies are a group of autoimmune diseases which result in skeletal muscle weakness. In addition to inflammatory pathology, it has been speculated that non-inflammatory mechanisms, and possibly secondary MAD-deficiency, may potentially contribute to weakness in these conditions. Methods: We investigated for an association between these two myopathic processes through two complementary methods. Firstly, muscle biopsy records in South Australia over a 17-year period were retrospectively reviewed for diagnosis of myositis or MAD-deficiency, as well as associated clinical features. Secondly, a prospective arm histochemically tested all incident biopsy specimens over a 12-month period for MAD-deficiency. Results: In the retrospective arm, 30 MAD-deficient cases were identified (1.3% of all biopsies), with no significant difference observed in overall rates of myositis diagnosis between patients with intact and deficient MAD activity (21.3% vs 26.7%, P = 0.47). No cases of MAD-deficiency were detected in the prospective arm, despite 39 cases of myositis being identified over this period. Conclusion: Secondary MAD deficiency is unlikely to be a major driver of symptoms in inflammatory myopathies.
RESUMO
Immune-mediated necrotising myopathy (IMNM) is a recently described entity. We describe a cohort of South Australian IMNM patients in order to define the spectrum of disease, characterise features that distinguish IMNM from other idiopathic inflammatory myopathy (IIM) subtypes and identify factors associated with clinically severe disease. Subjects were identified from the South Australian Myositis Database (SAMD), a histologically defined registry. Consecutive muscle sections from patients with IMNM (nâ¯=â¯62), other forms of IIM (nâ¯=â¯60) and histologically normal muscle (nâ¯=â¯17) were stained using immunohistochemistry and graded. Clinical information was collected from the SAMD and through retrospective chart review. IMNM patients displayed clinical and histological heterogeneity. While most (67%) were profoundly weak at presentation, 24% exhibited mild to moderate weakness and 9% had normal power. Histological myonecrosis ranged from minor to florid. The amount of myofibre complement deposition was closely associated with clinical severity. Patients of Aboriginal and Torres Strait Islander heritage and those with anti-SRP autoantibodies present with a severe phenotype. Despite intense immunotherapy, few IMNM patients recovered full power at one year follow up. The identification of clinical, serological and histological features which are associated with severe forms of the disease may have diagnostic and therapeutic utility.
Assuntos
Doenças Autoimunes , Miosite , Havaiano Nativo ou Outro Ilhéu do Pacífico/etnologia , Necrose , Sistema de Registros , Idoso , Autoanticorpos/sangue , Doenças Autoimunes/etnologia , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Doenças Autoimunes/fisiopatologia , Feminino , Seguimentos , Humanos , Imunoterapia , Masculino , Pessoa de Meia-Idade , Miosite/etnologia , Miosite/imunologia , Miosite/patologia , Miosite/fisiopatologia , Necrose/etnologia , Necrose/imunologia , Necrose/patologia , Necrose/fisiopatologia , Fenótipo , Estudos Retrospectivos , Índice de Gravidade de Doença , Austrália do Sul/etnologiaRESUMO
INTRODUCTION: High Mobility Group Box Protein 1 (HMGB1) is a DNA-binding protein that exerts inflammatory or pro-repair effects upon translocation from the nucleus. We postulate aberrant HMGB1 expression in immune-mediated necrotising myopathy (IMNM). METHODS: Herein, we compare HMGB1 expression (serological and sarcoplasmic) in patients with IMNM with that of other myositis subtypes using immunohistochemistry and ELISA. RESULTS: IMNM (n = 62) and inclusion body myositis (IBM, n = 14) patients had increased sarcoplasmic HMGB1 compared with other myositis patients (n = 46). Sarcoplasmic HMGB1 expression correlated with muscle weakness and histological myonecrosis, inflammation, regeneration and autophagy. Serum HMGB1 levels were elevated in patients with IMNM, dermatomyositis and polymositis, and those myositis patients with extramuscular inflammatory features. DISCUSSION: Aberrant HMGB1 expression occurs in myositis patients and correlates with weakness. A unique expression profile of elevated sarcoplasmic and serum HMGB1 was detected in IMNM.
RESUMO
The authors describe a simple and cost-effective method of immunostaining semithin epoxy resin sections of peripheral nerve for light microscopy with antibodies to myelin protein zero, peripheral myelin protein 22, myelin basic protein, and neurofilament protein 200 using a combined technique of surface etching with sodium ethoxide and heat-induced antigen retrieval.
Assuntos
Resinas Epóxi , Imuno-Histoquímica/métodos , Proteínas do Tecido Nervoso/análise , Nervos Periféricos/química , Anticorpos , Etanol/análogos & derivados , Temperatura Alta , Humanos , Proteína Básica da Mielina , Proteína P0 da Mielina , Proteínas da Mielina , Proteínas de NeurofilamentosRESUMO
The purpose of the study was to undertake an audit of the use of rituximab in refractory idiopathic inflammatory myositis (IIM). Patients with biopsy-proven refractory IIM treated with rituximab, attending the rheumatology clinic at the Royal Adelaide Hospital were identified by searching the electronic database of patient records from 2007 to March 2013. Seven cases (five women, two men), age range 31 to 68 years with histologically confirmed IIM, were identified. All patients had received rituximab following other immunosuppressive agents, including prednisolone. With rituximab, all patients showed improvement in muscle strength and reduction in muscle enzyme levels and required reduced doses of oral corticosteroids. Response continued for at least 5 months from the initial treatment. No serious adverse events were noted, and there were no infections during the study period. This case series supports the use of B cell depletion therapy with rituximab as an effective treatment for patients with refractory IIM.
Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Imunossupressores/uso terapêutico , Miosite/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Depleção Linfocítica , Masculino , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Rituximab , Resultado do TratamentoRESUMO
Pathological studies, including novel teased peripheral nerve fiber studies, were performed in a patient who presented with a rapidly progressive, lower motor neuron syndrome and high titer of immunoglobulin M anti-GM1 ganglioside antibody. In the central nervous system, there was a severe loss of motor neurons and central chromatolysis with ubiquitin immunopositive cytoplasmic inclusions in residual motor neurons. In the peripheral nervous system, axonal degeneration of myelinated fibers in the anterior nerve roots was evident. Pathologic evidence of sensory nerve involvement was also found despite the absence of clinical or electrophysiological sensory abnormalities. Sectional studies of single myelinated nerve fibers from an antemortem sural nerve biopsy showed remyelination and globular paranodal swellings due to focal complex myelin folding and degeneration in 13% of fibers. Postmortem studies of the sural nerves 4 weeks later showed paranodal demyelination (90% of fibers), but no paranodal swellings and similar findings were present in samples of the ulnar, radial, median, tibial, and common peroneal nerves. Paranodal abnormalities of enlargement of the adaxonal space, myelin degeneration, and axonal compaction were found on cross-sectional studies of individual teased fibers, which on conventional light microscopic assessment appeared normal. These changes suggest a disturbance of paranodal axonal-myelin adhesion due to binding of the anti-GM1 ganglioside antibody to the common epitope known to be present on the myelin sheath and nodal axolemma in the paranodal region of both motor and sensory nerves.
Assuntos
Sistema Nervoso Central/patologia , Doença dos Neurônios Motores/patologia , Sistema Nervoso Periférico/patologia , Adulto , Sistema Nervoso Central/ultraestrutura , Feminino , Gangliosídeo G(M1)/imunologia , Humanos , Imunoglobulina M/sangue , Microscopia Eletrônica , Doença dos Neurônios Motores/fisiopatologia , Bainha de Mielina/patologia , Bainha de Mielina/ultraestrutura , Degeneração Neural , Sistema Nervoso Periférico/ultraestruturaRESUMO
The pathogenesis of tomacula in mice with a null mutation of the myelin-associated glycoprotein (MAG) gene is not well understood. This study, using a novel teased nerve fiber technique, demonstrates that tomacula in MAG-deficient mice are formed by redundant myelin infoldings and outfoldings in the paranodal regions as early as 4 weeks after birth and increase in size and frequency with age. Although tomacula show degenerative changes with increasing age, there was no significant evidence of demyelination/remyelination. Longitudinal sections of normal teased nerve fibers show early redundant myelin foldings in externally normal paranodal regions. These data and the absence of internodal tomacula support a role for MAG in the maintenance of myelin at the paranodal regions.